Ignite Creation Date:
2024-05-05 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00060554
Status:
WITHDRAWN
Last Update Posted:
2009-11-03
First Post:
2003-05-07
Brief Title:
A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention PCI63133WITHDRAWN
Sponsor:
Schering-Plough
Organization:
Schering-Plough
Study Overview
Official Title:
None
Status:
WITHDRAWN
Status Verified Date:
2009-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Drug sold to Sanofi-Aventis who sold it to GSK OBS no longer owns study and does not have data
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research study is to obtain experience in the use of fondaparinux Arixtra as compared to heparin when administered to patients who undergo percutaneous coronary intervention PCI PCI is a mechanical procedure used to widen the narrowing in a coronary artery in patients with symptomatic coronary artery disease Fondaparinux and heparin are drugs that inhibit blood clotting
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None